Idea
Scientific literature
As seen in:
Press
"The potential applications of RCas9 are seemingly boundless."
"Such an approach has the potential to be applied to diverse transcript types in multiple cell systems"
.png)
.png)
Scientific literature
As seen in:
Press
"Researchers [have used] CRISPR to fix problems in RNA rather than to change DNA, a promising step for a group of diseases, including Huntington’s and amyotrophic lateral sclerosis, that have no cure."
Proof of concept
Technical strategy
Business strategy
Early-stage operations
Experience
Co-founder and Chief Technology Officer at Locana, Inc.
Awards
STAT Wunderkind: selected during a nationwide search for "the next generation of scientific superstars"
BIOCOM Catalyst: among 15 awardees to have made unique contributions to the biotech community in Southern California
Press
"Locana bags $55M for RNA-targeting gene therapies"
"Locana, Fueled With $55M, Looks to Develop Fixes for Faulty RNA"
Series A
Preclinical development
Published preclinical studies
As seen in:
Co-first author of a series of preclinical studies that establish the safety and efficacy of RNA-targeting Cas9 in a model of the most common type of adult-onset muscular dystrophy.
